Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
AstraZeneca
MedSIR
NRG Oncology
Thomas Jefferson University
National Cancer Institute (NCI)
Stanford University
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
Duke University
US Oncology Research
Dana-Farber Cancer Institute
Eli Lilly and Company
DEKK-TEC, Inc.
Case Comprehensive Cancer Center
Novartis
Stanford University
Novartis
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of California, San Francisco
University of Washington
Merck Sharp & Dohme LLC
Novartis
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline
Virginia Commonwealth University
Baylor Breast Care Center
Dana-Farber Cancer Institute
INSYS Therapeutics Inc
Case Comprehensive Cancer Center
Dana-Farber Cancer Institute